Changes in glucose tolerance after endoscopic retrograde cholangiopancreatography

Z TULASSAY, * J PAPP, M SZATHMÁRI, S KISFALUDY, L KORÁNYI, AND G TAMÁS
From the Medical Clinic and Endoscopic Centre of Semmelweis University, Budapest

SUMMARY Changes in oral glucose tolerance have been studied in patients subjected to endoscopic retrograde pancreatography. Glucose tolerance is impaired 72 hours after ductography, and significant changes can still be seen even after one month; glucose tolerance returns to normal six to 12 months after pancreatography. In an attempt to discover the mechanism underlying impaired tolerance serial measurements were made of plasma insulin and glucagon levels. The observation that the ratio I/G decreased in these patients indicates that enhanced glucagon release, probably due to mechanical and/or osmotic injury, may be responsible for the hyperglycaemia that is observed.

Endoscopic retrograde cholangiopancreatography (ERCP) has in the last few years become the most important diagnostic procedure in morphological abnormalities of the pancreas, particularly in cases where surgical correction is envisaged. The risks of the procedure have been outlined in studies involving a great number of patients. The short-lived functional alterations that follow the filling of the pancreatic duct with a radiographic contrast medium have also been studied. It is still unresolved, however, whether in the absence of clinical or biochemical manifestations there occur subtle abnormalities in the pancreas that are detectable by repeated investigations over a longer period of time. Whether ductography affects the function of the islet cells has not been settled either. The present study was undertaken to clarify some of these problems.

Methods

The technique of ERCP has been described in detail previously. Premedication consisted of pharyngeal anaesthesia with xylocaine spray (Lidocaine) and the intravenous administration of 100 mg pethidine and 0.5 mg atropine; diatrizoate 60% (Uromiro, Bracco Ltd, Milan) was used as a radio-opaque medium. The total amount of radiographic contrast material delivered into the Wirsungian duct was also measured. Serum amylase levels were determined before and 10, 20, 30, 40, 60, 90, 120, and 240 minutes, and six, 24, and 48 hours after the ERCP. When evaluating the relationship between changes in glucose tolerance, amount of injected radioopaque medium, and the increase in serum amylase levels, values obtained at peak amylase values were considered, irrespective of the timing (Figure).

All patients exhibited normal morphology of the duct of Wirsung. In 10 cases bile duct abnormality could be also excluded, although ERCP had been indicated because of suggested biliary tract disease. The remaining five patients had choledolithiasis.

Oral glucose tolerance was studied, using a standard load of 50 g, in 15 patients before and 72 hours, one, six, and 12 months after ERCP. With the exception of five patients who had gallstones, insulin and glucagon levels were established during the glucose tolerance test; of the 10 patients thus studied six had impaired, while four had normal, glucose tolerance.

Ten patients acted as controls (control I). They had previously been shown to have no abnormalities of carbohydrate metabolism and were not subjected to ERCP. In another 10 patients (control II), after a glucose tolerance test yielding normal results, upper panendoscopy was carried out using the same premedication as that described for ERCP. Glucose tolerance tests were repeated 72 hours and one month thereafter. Insulin was measured by the Boehringer insulin RIA test, glucagon by the C terminal (pancreatic glucagon) specific antibody, using standard radioimmunoassay techniques. The recommendations of the European Diabetic Associa-
tion were considered when classifying the individual glucose tolerance curves (Table 1). Using these criteria, the patients were classified as having normal, borderline, or pathological glucose tolerance. On qualitative analysis of the patients' response, the number of normal, borderline, and pathological curves was considered. For the quantitative analysis of glucose tolerance in the individual patients, the area below each curve was determined, and the mean values and standard deviations for each time point were compared using the t test. The area below each insulin or glucagon response curve was similarly analysed; the changes in these two parameters were also compared with each other by calculating the ratio insulin to glucagon level (I/G).

Results

None of the 15 patients developed acute pancreatitis as a result of ERCP. Before ERCP, all patients had normal glucose tolerance. After pancreatography, seven patients exhibited pathological glucose tolerance curves, four of whom had abnormal values for blood glucose during loading even after one month. However, at the six and 12 months' follow-up the patients showed no abnormality in glucose tolerance after ERCP (Table 1). All control subjects showed normal glucose tolerance 72 hours and one month after the first loading test. Thus the results are reproducible, neither premedication nor upper panendoscopy affecting per se the glucose tolerance of the patients.

Table 2 summarises the results obtained by planimetric analysis of the curves. There was a statistically significant increase of the area below the individual glucose tolerance curves 72 hours after pancreatography, while the results obtained after one month were not different from the initial values.

The data of planimetric analysis of the curves representing the changes in plasma insulin and glucagon levels during oral glucose loading have been also summarised in Table 2. The glucose tolerance study performed 72 hours after pancreatography revealed enhanced release of both hormones, the increase in glucagon being substantially more marked; this accounts for the sharp drop in the ratio I/G, which was statistically significant. Repeated study after one month failed to reveal this differential response in pancreatic insulin and glucagon release. Impairment of glucose tolerance and the changes in I/G ratio are significantly correlated (at 72 hours: r=0.87, p<0.05).

In five of the seven patients who showed impaired
glucose tolerance there was also a rise in serum amylase levels. Pathological serum amylase values were found in eight of the 15 patients subjected to pancreatography. The relationship between glucose tolerance, volume of the radiographic contrast medium injected, and the maximum rise in serum amylase is shown in the Figure.

**Discussion**

Diminished glucose tolerance has been amply demonstrated to occur in acute pancreatitis. About 30% of patients with acute pancreatitis developed glycosuria, and raised blood glucose levels were found in about 50%.

Blood glucose became normal after the acute phase of the disease had subsided; however, glucose tolerance was impaired for several weeks in 10% of the patients. Diabetes mellitus has been shown to persist in 2% of the patients after an episode of acute pancreatitis. Available data also indicate that, in the early phase of acute pancreatitis, impairment of glucose tolerance is due to abnormal functioning of the pancreatic alpha cells, while diabetes that develops after necrotising pancreatitis is the result of damaged beta cell function.

It has been suggested by Adlung that acute pancreatitis is followed by relative insulin deficiency, the insulin present in the serum being part of the altered chemical structure and diminished biological activity.

Two per cent to 3% of patients subjected to ERCP develop acute pancreatitis. In view of the relationship between acute pancreatitis and diabetes mellitus there is a small but sizable number of patients who might become diabetic after such a study.

The frequency of biochemical abnormalities without clinical manifestations is much higher, about 40 to 50%, after retrograde pancreatography. Thus about half of the patients will exhibit the laboratory changes usually observed in acute pancreatitis; these are, however, transient and are not accompanied by clinical symptoms. It seemed interesting to assess whether glucose tolerance was affected in such patients. Our results have shown that, 72 hours after retrograde pancreatography, a substantial number of patients exhibit impaired glucose tolerance. Marked changes in glucose tolerance may persist even one month after ERCP.

The most plausible explanation for the hyperglycaemia prevailing after retrograde pancreatography seems to be the increased glucagon release which is indicated by the changes in the insulin to glucagon ratio. This is in line with the suggestion made by Banks, who attributed the alterations in carbohydrate metabolism associated with acute pancreatitis to abnormal function of the alpha cells.

The extent of laboratory changes manifested in enzyme and hormone levels in the blood depends on the intraluminal pressure in the pancreatic duct—that is, the amount of radiographic medium injected.

The data shown in the Figure indicate that there is a relationship between the impairment of glucose tolerance and the increase of intraluminal pressure. It is thus conceivable that the mechanical and osmotic challenge is transmitted also to the islet cells, resulting in impaired glucose tolerance. As the alpha cells have a more peripheral location in the pancreatic islets, it might be expected that glucagon release will be enhanced.

The importance of impaired glucose tolerance after retrograde pancreatography is evident in patients with diabetes. It should also be considered, however, in non-diabetic patients, particularly if other predisposing factors—for example, genetic ones—can be revealed. In such cases it seems appropriate, in addition to careful judgement of the indication for ERCP and more vigorous follow-up of the patient after study, to seek ways of preventing this development.

### Table 2  Planimetric analysis of glucose tolerance curves

<table>
<thead>
<tr>
<th>Group</th>
<th>Before ERCP</th>
<th>After 72 hours</th>
<th>After 1 month</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Mean (SD)</td>
<td>Mean (SD)</td>
<td>Mean (SD)</td>
</tr>
<tr>
<td>Patients subjected to ERCP</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Blood glucose</td>
<td>742.6 (98.12)</td>
<td>854.0 (163.4)</td>
<td>787.2 (118.8)</td>
</tr>
<tr>
<td>Insulin</td>
<td>60754 (19385)</td>
<td>78980 (8506)</td>
<td>68044 (8506)</td>
</tr>
<tr>
<td>Glucagon</td>
<td>8377 (3883)</td>
<td>15079 (3434)</td>
<td>8796 (4607)</td>
</tr>
<tr>
<td>I/G ratio</td>
<td>9.4 (0.91)</td>
<td>5.47 (0.68)</td>
<td>7.6 (2.01)</td>
</tr>
<tr>
<td>Control I patients</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Blood glucose</td>
<td>726 (72.2)</td>
<td>704 (43.6)</td>
<td>704 (51.0)</td>
</tr>
<tr>
<td>Control II patients</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Blood glucose</td>
<td>734.7 (38.3)</td>
<td>731 (28.5)</td>
<td>755.0 (27.6)</td>
</tr>
</tbody>
</table>

| n = number of cases |
| Mean = values are expressed in mmol/l x min for glucose and pmol/l x min for insulin and glucagon |
| p = degree of significance compared to values obtained prior to ERCP |
| ns = not significant |
References


